Carregant...
Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
Up to 90% of patients with tuberous sclerosis complex (TSC) have epilepsy, and in over half of patients seizure control cannot be achieved by regular antiepileptic drugs. The underlying problem is mTOR hyperactivation due to loss of function of the TSC proteins. Treatment with everolimus, an mTOR in...
Guardat en:
| Publicat a: | Ther Clin Risk Manag |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6666377/ https://ncbi.nlm.nih.gov/pubmed/31440057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S145630 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|